Zetia Cost in Michigan 2026: Prices, Insurance, Medicaid, and Compounding

What Does Zetia Actually Cost in Michigan Right Now?

Generic ezetimibe 10 mg costs approximately $15 per month at most Michigan pharmacies when patients use a GoodRx or similar discount card in 2026. Brand-name Zetia from Merck carries a manufacturer list price of roughly $380 per month, a figure that most commercially insured patients never pay out of pocket due to copay assistance and tiered formularies.

The gap between $15 and $380 for the same therapeutic molecule is not accidental. Ezetimibe's patent expired in 2017, opening the market to multiple generic manufacturers and driving retail cash prices sharply downward. The FDA maintains a searchable database of approved generic ezetimibe products at accessdata.fda.gov, which currently lists several generic sponsors including Glenmark, Aurobindo, and Dr. Reddy's Laboratories. [1]

At major Michigan chains such as Meijer, CVS, Walmart, and Walgreens, a 30-day supply of generic ezetimibe 10 mg commonly runs between $12 and $18 with a free GoodRx coupon applied at the register. Meijer's $4/$10 generic program has historically included ezetimibe on its formulary, though patients should confirm current tier status directly with the pharmacy. Walmart's $4 generic program similarly covers selected cardiovascular drugs; ezetimibe has appeared on that list at select Michigan locations. [2]

Patients who pay the brand Zetia list price without insurance are a small minority. Still, knowing that number matters when evaluating insurance tiers or deciding whether a PA appeal is worth pursuing. For uninsured Michigan residents, the brand price is prohibitive; for those patients, generic cash-pay or Medicaid is the practical path.

LDL-C control itself carries measurable cost-of-illness weight. The CDC estimates cardiovascular disease costs the U.S. economy more than $216 billion annually in direct medical costs, making medication adherence an economic as well as clinical priority. [3]

How Michigan Medicaid Covers Ezetimibe in 2026

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers ezetimibe, but a prior authorization is required before the claim will process at the pharmacy. Prescribers must document that the patient has an elevated LDL-C consistent with guidelines, is already on statin therapy or has a documented statin intolerance, and that a high-intensity statin alone is insufficient or contraindicated.

The Michigan Department of Health and Human Services publishes preferred drug lists for its managed care organizations. Ezetimibe appears on multiple Michigan Medicaid MCO formularies as a non-preferred or preferred agent depending on the plan, but prior authorization criteria are consistent across plans: documented diagnosis of hyperlipidemia (ICD-10 E78.x) plus evidence of inadequate LDL-C control. [4]

To submit a PA for ezetimibe under Michigan Medicaid, the prescriber typically needs:

• A fasting lipid panel showing LDL-C above goal
• Documentation of current statin dose and duration
• Clinical justification if the patient is statin-intolerant (e.g., myopathy, elevated CK, or documented rhabdomyolysis per NCBI MedlinePlus guidance) [5]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "In adults 40-75 years of age with LDL-C 70-189 mg/dL, use of a cholesterol-lowering medication is recommended if the 10-year CVD risk is 10% or higher." [6] That guideline language supports PA approvals when LDL-C remains above target on maximally tolerated statin alone.

Once approved, Medicaid covers ezetimibe at the standard Medicaid drug copay, which for most Michigan enrollees is $0 to $4 per prescription. Approvals typically cover 12 months before renewal is required, though each MCO sets its own PA duration policy.

PA denials can be appealed. Michigan Medicaid enrollees have the right to a formulary exception and a state fair hearing if the exception is denied. The Michigan Department of Health and Human Services outlines this process at michigan.gov, and CMS guidance on Part D and Medicaid appeals is available at cms.gov. [7]

Is Compounded Ezetimibe Legal in Michigan?

Yes. Licensed 503A compounding pharmacies in Michigan may legally prepare ezetimibe for individual patients when a valid patient-specific prescription exists. Compounded ezetimibe is not FDA-approved as a finished drug, so these preparations fall under state pharmacy board oversight and federal 503A rules rather than the standard NDA pathway. [8]

Section 503A of the Federal Food, Drug, and Cosmetic Act, as described by the FDA, permits compounding pharmacies to prepare drugs for individual patients based on a prescriber's order when a commercially available product does not meet that patient's clinical needs. [9] A prescriber citing a clinical reason, such as a specific dose not available commercially or a documented excipient allergy, may satisfy that standard for ezetimibe.

In Michigan, compounding pharmacies must hold an active license from the Michigan Board of Pharmacy and comply with USP Chapter 795 standards for non-sterile preparations. The Michigan Board of Pharmacy lists licensed pharmacies at its public registry. [10]

Cost can drop to near $0 per month for patients in telehealth programs that bundle compounded ezetimibe at no additional charge. This pricing model reflects the low raw-material cost of ezetimibe API and the prescribing platform subsidizing the medication as part of a broader cardiovascular or metabolic health subscription. Patients should verify that the compounding pharmacy serving them holds a current Michigan license and that the prescriber has documented a legitimate clinical reason for compounding rather than dispensing a commercially available generic.

The FDA's guidance document "Compounding Under the Federal Food, Drug, and Cosmetic Act" clarifies that compounders may not make copies of commercially available drugs without a specific clinical rationale. [9] Because generic ezetimibe 10 mg tablets are widely available and inexpensive, prescribers should document the clinical reason carefully to satisfy 503A requirements.

How Ezetimibe Works and Why LDL Reduction Matters

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush-border membrane, reducing cholesterol absorption by approximately 54% at the 10 mg dose. [11] This mechanism complements statin therapy, which targets hepatic cholesterol synthesis via HMG-CoA reductase inhibition; combining the two drugs produces additive LDL-C reductions beyond what either agent achieves alone.

The IMPROVE-IT trial (N=18,144), published in the New England Journal of Medicine in 2015, remains the defining outcomes evidence for ezetimibe. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the placebo group, an absolute risk reduction of 2.0 percentage points and a hazard ratio of 0.936 (95% CI 0.887 to 0.988, P<0.001). [12]

The IMPROVE-IT investigators concluded: "The trial showed that adding ezetimibe to statin therapy resulted in a significant reduction in the composite primary endpoint." [12] That 2-percentage-point absolute reduction in a high-risk secondary-prevention population established the clinical value of ezetimibe even before PCSK9 inhibitors entered practice.

Each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C is associated with a 22% reduction in major vascular events per the Cholesterol Treatment Trialists' Collaboration meta-analysis of 26 randomized trials (N=170,000). [13] This dose-response relationship means that the incremental LDL-C lowering from ezetimibe translates into proportional event-rate reductions, which supports its use as an add-on therapy.

The ACC/AHA 2022 Guideline on Nonstatin Therapies recommends ezetimibe as first-line nonstatin therapy in patients who require additional LDL-C reduction beyond maximally tolerated statin dose. [14] This guideline position gives Michigan prescribers and Medicaid PA reviewers a clear evidence-based framework for approvals.

Which Michigan Insurance Plans Cover Ezetimibe?

Most commercial insurance plans operating in Michigan cover generic ezetimibe on Tier 1 or Tier 2. Brand Zetia is typically Tier 3 or higher, with copays ranging from $40 to $100 per month after deductible. Patients whose plans cover only brand Zetia at a high tier should ask the prescriber to specify "generic ezetimibe" on the prescription, as substitution is legally permitted in Michigan.

Michigan Blue Cross Blue Shield (BCBS), Priority Health, Molina Healthcare, and HAP all list generic ezetimibe on their commercial formularies as of 2026 plan year filings. Tier placement and PA requirements vary; patients can look up tier status using each insurer's online formulary tool or call the member services number on their insurance card. [15]

Employer-sponsored plans governed by ERISA may differ from state-regulated individual and small-group plans. For ERISA plans, Michigan state insurance laws, including any mandated formulary inclusion requirements, do not apply. Employees on ERISA plans who face high ezetimibe copays should contact their HR benefits department to request a formulary exception.

For patients on Medicare Part D in Michigan, ezetimibe coverage depends on the individual plan's formulary. The Medicare Plan Finder at medicare.gov allows beneficiaries to enter their specific drugs and compare out-of-pocket costs across all available Part D plans in their zip code. [16] In 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D applies, which may reduce total annual exposure for patients on multiple cardiovascular drugs.

Manufacturer Savings Cards and Patient Assistance Programs

Merck offers a savings card for brand-name Zetia that can reduce the copay to as low as $0 per month for eligible commercially insured patients. The program does not apply to Medicaid, Medicare, or other government-funded coverage. Eligibility and monthly savings limits are subject to change; current terms are posted on Merck's patient assistance page and at merck.com. [17]

For uninsured patients who cannot afford even generic cash prices, the Merck Patient Assistance Program (PAP) and NeedyMeds may provide brand or generic ezetimibe at no cost. NeedyMeds maintains a database of assistance programs at needymeds.org, and the Partnership for Prescription Assistance connects patients to manufacturer programs. [18]

Generic manufacturers including Glenmark and Aurobindo do not typically offer branded savings cards, but their products are priced low enough that discount programs such as GoodRx, RxSaver, and Blink Health bring out-of-pocket costs to $10 to $18 per month at most Michigan pharmacies without any manufacturer involvement. [2]

Patients should compare the GoodRx price against their insurance copay at each refill. For Tier 2 generics with a $20 copay, paying cash with GoodRx at $12 is often cheaper. Pharmacists in Michigan are permitted to inform patients of lower cash prices when asked, consistent with CMS transparency rules effective since 2020. [19]

Telehealth Prescribing of Ezetimibe in Michigan

Michigan law permits telehealth prescribing of ezetimibe. A Michigan-licensed prescriber may issue a valid prescription for ezetimibe following a synchronous audio-video telehealth visit or, in some circumstances, an asynchronous store-and-forward encounter, provided the prescriber establishes a valid patient-provider relationship and documents clinical justification. [20]

Ezetimibe is not a controlled substance, so the DEA's telehealth prescribing restrictions for Schedule II-V drugs do not apply. The standard of care for an ezetimibe prescription via telehealth in Michigan mirrors in-person prescribing: the prescriber needs a documented lipid panel, cardiovascular risk assessment, and medication history.

HealthRX's Michigan-licensed providers routinely prescribe ezetimibe as part of lipid management protocols. Patients typically upload a recent lipid panel (within 6 to 12 months) during intake, complete a brief cardiovascular risk questionnaire, and receive a prescription sent electronically to their preferred Michigan pharmacy. The entire process can be completed in under 20 minutes for straightforward hyperlipidemia cases.

Michigan's telehealth parity law (Public Act 190 of 2020) requires most commercial insurers to reimburse telehealth visits at the same rate as in-person visits. [20] This means the cost of the prescribing encounter for ezetimibe is the standard office-visit copay for the patient's plan, not an additional out-of-pocket expense.

The following framework captures how HealthRX clinicians sequence ezetimibe prescribing decisions for Michigan patients based on access pathway:

HealthRX Michigan Ezetimibe Access Decision Framework (2026)

1. Patient on Medicaid: initiate PA with LDL-C lab and statin documentation; expect $0 to $4 copay after approval.
2. Patient with commercial insurance: confirm generic ezetimibe tier; if Tier 1 or 2, proceed; if Tier 3 or brand-only, substitute generic and apply GoodRx if copay exceeds $15.
3. Patient uninsured or underinsured: prescribe generic ezetimibe 10 mg; apply GoodRx at Meijer, Walmart, or Costco for $10 to $18 cash price.
4. Patient in telehealth program with compounding access: verify Michigan 503A pharmacy license; confirm prescriber has documented clinical rationale per FDA 503A requirements; cost may be $0 within subscription.
5. Patient on Medicare Part D: use medicare.gov Plan Finder to identify lowest-cost plan covering generic ezetimibe; 2026 $2,000 annual OOP cap applies.

Safety Profile, Monitoring, and Drug Interactions

Ezetimibe has a favorable safety record established across the IMPROVE-IT trial's 18,144-patient, 6-year dataset and confirmed in post-marketing surveillance. The most common adverse effects are upper respiratory tract infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), and sinusitis (2.8%) per the FDA-approved prescribing information. [1]

Hepatotoxicity with ezetimibe monotherapy is rare. The FDA label notes that clinically significant transaminase elevations occurred in 1.3% of patients receiving ezetimibe plus statin versus 0.4% receiving statin alone in controlled trials, a rate that suggests the combination rather than ezetimibe alone drives the signal. Baseline liver function testing is not required before initiating ezetimibe per current labeling. [1]

Myopathy and rhabdomyolysis have been reported post-marketing, primarily in patients also taking statins or fibrates. The risk is low in absolute terms; IMPROVE-IT found no significant difference in myopathy rates between arms. [12] Patients who develop unexplained muscle pain or weakness on ezetimibe plus statin should have creatine kinase measured per NCBI guidance. [5]

Cyclosporine significantly increases ezetimibe plasma exposure (AUC increase up to 3.4-fold); concurrent use requires caution and dose adjustment review. [1] Bile acid sequestrants such as cholestyramine reduce ezetimibe absorption by approximately 55%; ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant. [1]

Pregnancy category: ezetimibe is contraindicated in pregnancy (FDA category X when combined with a statin) due to statin teratogenicity, though ezetimibe alone has not been shown to cause fetal harm in animal studies. [1] Women of childbearing age should use effective contraception during therapy. ACOG guidance on lipid management in pregnancy is available at acog.org. [21]

Renal impairment does not require dose adjustment. Severe hepatic impairment (Child-Pugh score 7 to 15) is a contraindication due to unknown pharmacokinetics in that population. [1]

Dosing, Administration, and Monitoring Targets

The approved dose is ezetimibe 10 mg orally once daily, taken with or without food, at any time of day. No titration schedule is needed. The FDA-approved labeling specifies that ezetimibe can be taken at the same time as an HMG-CoA reductase inhibitor (statin) for convenience. [1]

LDL-C response is typically evident within 2 weeks of initiating therapy. A fasting lipid panel at 4 to 12 weeks after initiation confirms response, consistent with ACC/AHA 2022 monitoring recommendations. [14] Target LDL-C depends on risk category:

• Very high risk (prior ASCVD event): LDL-C <55 mg/dL per 2022 ACC/AHA guidance [14]
• High risk (diabetes, 10-year risk 7.5% to <20%): LDL-C <70 mg/dL [14]
• Intermediate risk (10-year risk 7.5% to 20%): LDL-C <70 mg/dL on combination therapy [14]

Michigan prescribers using telehealth should confirm a follow-up lipid panel is ordered at the time of the initial ezetimibe prescription. Most commercial labs in Michigan (Quest Diagnostics, LabCorp, Spectrum Health Lab) accept electronic orders from telehealth providers; results route back to the ordering provider's electronic health record within 24 to 48 hours.

The ATP IV-informed approach reflected in 2019 ACC/AHA Primary Prevention guidelines recommends reassessing global ASCVD risk at each lipid-panel follow-up and adjusting therapy, including adding PCSK9 inhibitors (evolocumab or alirocumab), if LDL-C remains above goal on maximally tolerated statin plus ezetimibe. [6] That stepped approach makes ezetimibe the logical second-tier agent before the substantially higher-cost injectable therapies are considered, supporting both clinical and economic reasoning for Michigan patients and payers.